Team #5: Clinical Trials
Designing Clinical Trials to Test New Therapies
Researchers in Team 5 will design and conduct clinical trials of new t-AML drugs, starting with a current drug candidate that is ready for immediate trial, and extending to multiple new targets discovered along the way.
New treatment approaches are desperately needed for patients with t-AML because there are no long-term survivors from this disease. University of Chicago researchers have a vision to develop new, personalized therapies to treat this disease through bi-directional basic and clinical research. In other words, laboratory research will shed light on the biological complexities of t-AML, which will guide the development of clinical trials. These trials, in turn, will provide patient samples for researchers to understand the biological effects of chemotherapeutic drugs.
Investigators in Team 5 are developing clinical trials for patients with t-AML and AML arising in elderly patients. Using a standard treatment protocol (developed recently at the University of Chicago) as the framework for these trials, investigators will incorporate novel agents and test their effectiveness in patients. One of the first trials will include a, which has shown promise for inducing and maintaining patients in remission. Subsequently, novel drugs discovered by Team 3 will be tested.
The goal of these trials is to maintain patients in remission and to determine theeffects of these drugs by collecting patient samples for testing. Upon enrollment, patients will provide samples of both healthy and leukemic cells for genetic analysis. Patients will then receive , and additional samples will be collected during the course of treatment. The team will perform hematopoietic transplants in patients who respond to the . Researchers will determine from the collected samples whether the patient’s genetic make-up influences drug response. In addition, leukemic stem cells will be isolated for use in projects led by Team 3 and Team 4 to identify new drugs for clinical testing.
Team 5 is integrating the data generated by Team 1, Team 2, Team 3, Team 4 and Team 6 to develop and test new therapies for t-AML in clinical trials.
Check for future updates.